{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-017369","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.392745+00:00","generated_at":"2026-05-16T22:19:46.501197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tonix Q3 2025 net loss widens to $32M; cash $190.1M; Tonmya launch in November","bullets":["Net product revenue $3.3M (up from $2.8M YoY) from Zembrace/Tosymra sales.","Net loss $32.0M ($3.59 per share) vs $14.2M ($22.68 per share) in Q3 2024; SG&A surged to $25.7M on Tonmya launch prep.","Cash and equivalents $190.1M (Dec 2024: $98.8M); cash runway into Q1 2027 including $34.7M from Q4 2025 equity offerings.","Tonmya (fibromyalgia) launch in November 2025; 90 sales reps in field; WAC established; payer formulary placement for Tosymra in 2026.","Tonix in-licensed TNX-4800 (Lyme disease mAb) and announced Phase 2 collaboration for TNX-1500 (kidney transplant)."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-017369","json":"https://secwatch.observer/filing/0001999371-25-017369.json","markdown":"https://secwatch.observer/filing/0001999371-25-017369.md","text":"https://secwatch.observer/filing/0001999371-25-017369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125017369/0001999371-25-017369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125017369/tnxp-8k_111025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:19:46.501197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}